The Experts below are selected from a list of 5262 Experts worldwide ranked by ideXlab platform
Olga Di Fede - One of the best experts on this subject based on the ideXlab platform.
-
epidemiology clinical manifestations risk reduction and treatment strategies of Jaw Osteonecrosis in cancer patients exposed to antiresorptive agents
Future Oncology, 2014Co-Authors: Giuseppina Campisi, Stefano Fedele, Olga Di Fede, Vittorio Fusco, Giuseppe Pizzo, Alberto BedogniAbstract:Osteonecrosis of the Jaws (ONJ) is an adverse side event of bisphosphonates and denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-related events in patients with metastatic bone cancer and multiple myeloma. Available data suggest that 0-27.5% of individuals exposed to antiresorptive agents can develop ONJ. There is increasing evidence that avoidance of surgical trauma and infection to the Jawbones can minimize the risk of ONJ, but there are still a significant number of individuals who develop ONJ in the absence of these risk factors. Bone necrosis is almost irreversible and there is no definitive cure for ONJ with the exclusion, in certain cases, of surgical resection. However, most ONJ individuals are affected by advanced incurable cancer and are often managed with minimally invasive nonsurgical interventions in order to control Jawbone infections and painful symptoms. This article summarizes current knowledge of ONJ epidemiology, manifestations, risk-reduction and therapeutic strategies. Further research is needed in order to determine individual predisposition to ONJ and clarify the effectiveness of available treatments.
-
nonexposed variant of bisphosphonate associated Osteonecrosis of the Jaw a case series
The American Journal of Medicine, 2010Co-Authors: Stefano Fedele, Stephen Porter, Francesco Daiuto, Suad Aljohani, Paolo Vescovi, Maddalena Manfredi, Paolo G Arduino, Roberto Broccoletti, Anna Musciotto, Olga Di FedeAbstract:Abstract Purpose To report a case series of patients with the nonexposed variant of bisphosphonate-associated Osteonecrosis of the Jaw—a form of Jaw Osteonecrosis that does not manifest with necrotic bone exposure/mucosal fenestration. Methods Among 332 individuals referred to 5 clinical centers in Europe because of development of Jawbone abnormalities after or during exposure to bisphosphonates, we identified a total of 96 patients who presented with the nonexposed variant of Osteonecrosis. Relevant data were obtained via clinical notes; radiological investigations; patients' history, and referral letters. Results The most common clinical feature of nonexposed Osteonecrosis was Jaw bone pain (88/96; 91.6%); followed by sinus tract (51%), bone enlargement (36.4%); and gingival swelling (17.7%). No radiological abnormalities were identified in 29.1% (28/96) of patients. In 53.1% (51/96) of the patients; nonexposed Osteonecrosis subsequently evolved into frank bone exposure within 4.6 months (mean; 95% confidence interval; 3.6-5.6). Conclusions Clinicians should be highly vigilant to identify individuals with nonexposed Osteonecrosis, as the impact on epidemiological data and clinical trial design could be potentially significant. Although the present case series represents approximately 30% of all patients with bisphosphonates-associated Osteonecrosis observed at the study centers, further population-based prospective studies are needed to obtain robust epidemiological figures.
Sharon Elad - One of the best experts on this subject based on the ideXlab platform.
-
possible association between diabetes and bisphosphonate related Jaw Osteonecrosis
The Journal of Clinical Endocrinology and Metabolism, 2007Co-Authors: Mogher Khamaisi, Eran Regev, Noam Yarom, Batia Avni, Eran Leitersdorf, Itamar Raz, Sharon EladAbstract:Context: Bisphosphonate-related Osteonecrosis (BON) of the Jaws is a newly identified condition for which the exact mechanism involved in its pathogenesis remains obscure. Objective: The objective of the study was to evaluate whether diabetes mellitus (DM) may be a contributing factor in the development of BON. Design: From 2004 to 2006, 31 patients were diagnosed with BON. The diagnosis of BON was based on the medical and dental history of each patient as well as the observation of clinical signs and symptoms of this pathological process. DM was based on two consecutive fasting blood glucose levels above 7 mmol/liter. Setting: The study was completed in the Hebrew University-Hadassah Hospital referral center. Results: Of the 31 patients with BON, 18 (58%) were found to have DM or impaired fasting glucose. The proportion of diabetic patients was much higher than expected relative to the incidence of DM in the general population (14%) and compared with the proportion of diabetic patients in a control group...
Alberto Bedogni - One of the best experts on this subject based on the ideXlab platform.
-
epidemiology clinical manifestations risk reduction and treatment strategies of Jaw Osteonecrosis in cancer patients exposed to antiresorptive agents
Future Oncology, 2014Co-Authors: Giuseppina Campisi, Stefano Fedele, Olga Di Fede, Vittorio Fusco, Giuseppe Pizzo, Alberto BedogniAbstract:Osteonecrosis of the Jaws (ONJ) is an adverse side event of bisphosphonates and denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-related events in patients with metastatic bone cancer and multiple myeloma. Available data suggest that 0-27.5% of individuals exposed to antiresorptive agents can develop ONJ. There is increasing evidence that avoidance of surgical trauma and infection to the Jawbones can minimize the risk of ONJ, but there are still a significant number of individuals who develop ONJ in the absence of these risk factors. Bone necrosis is almost irreversible and there is no definitive cure for ONJ with the exclusion, in certain cases, of surgical resection. However, most ONJ individuals are affected by advanced incurable cancer and are often managed with minimally invasive nonsurgical interventions in order to control Jawbone infections and painful symptoms. This article summarizes current knowledge of ONJ epidemiology, manifestations, risk-reduction and therapeutic strategies. Further research is needed in order to determine individual predisposition to ONJ and clarify the effectiveness of available treatments.
Stefano Fedele - One of the best experts on this subject based on the ideXlab platform.
-
epidemiology clinical manifestations risk reduction and treatment strategies of Jaw Osteonecrosis in cancer patients exposed to antiresorptive agents
Future Oncology, 2014Co-Authors: Giuseppina Campisi, Stefano Fedele, Olga Di Fede, Vittorio Fusco, Giuseppe Pizzo, Alberto BedogniAbstract:Osteonecrosis of the Jaws (ONJ) is an adverse side event of bisphosphonates and denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-related events in patients with metastatic bone cancer and multiple myeloma. Available data suggest that 0-27.5% of individuals exposed to antiresorptive agents can develop ONJ. There is increasing evidence that avoidance of surgical trauma and infection to the Jawbones can minimize the risk of ONJ, but there are still a significant number of individuals who develop ONJ in the absence of these risk factors. Bone necrosis is almost irreversible and there is no definitive cure for ONJ with the exclusion, in certain cases, of surgical resection. However, most ONJ individuals are affected by advanced incurable cancer and are often managed with minimally invasive nonsurgical interventions in order to control Jawbone infections and painful symptoms. This article summarizes current knowledge of ONJ epidemiology, manifestations, risk-reduction and therapeutic strategies. Further research is needed in order to determine individual predisposition to ONJ and clarify the effectiveness of available treatments.
-
nonexposed variant of bisphosphonate associated Osteonecrosis of the Jaw a case series
The American Journal of Medicine, 2010Co-Authors: Stefano Fedele, Stephen Porter, Francesco Daiuto, Suad Aljohani, Paolo Vescovi, Maddalena Manfredi, Paolo G Arduino, Roberto Broccoletti, Anna Musciotto, Olga Di FedeAbstract:Abstract Purpose To report a case series of patients with the nonexposed variant of bisphosphonate-associated Osteonecrosis of the Jaw—a form of Jaw Osteonecrosis that does not manifest with necrotic bone exposure/mucosal fenestration. Methods Among 332 individuals referred to 5 clinical centers in Europe because of development of Jawbone abnormalities after or during exposure to bisphosphonates, we identified a total of 96 patients who presented with the nonexposed variant of Osteonecrosis. Relevant data were obtained via clinical notes; radiological investigations; patients' history, and referral letters. Results The most common clinical feature of nonexposed Osteonecrosis was Jaw bone pain (88/96; 91.6%); followed by sinus tract (51%), bone enlargement (36.4%); and gingival swelling (17.7%). No radiological abnormalities were identified in 29.1% (28/96) of patients. In 53.1% (51/96) of the patients; nonexposed Osteonecrosis subsequently evolved into frank bone exposure within 4.6 months (mean; 95% confidence interval; 3.6-5.6). Conclusions Clinicians should be highly vigilant to identify individuals with nonexposed Osteonecrosis, as the impact on epidemiological data and clinical trial design could be potentially significant. Although the present case series represents approximately 30% of all patients with bisphosphonates-associated Osteonecrosis observed at the study centers, further population-based prospective studies are needed to obtain robust epidemiological figures.
Mogher Khamaisi - One of the best experts on this subject based on the ideXlab platform.
-
possible association between diabetes and bisphosphonate related Jaw Osteonecrosis
The Journal of Clinical Endocrinology and Metabolism, 2007Co-Authors: Mogher Khamaisi, Eran Regev, Noam Yarom, Batia Avni, Eran Leitersdorf, Itamar Raz, Sharon EladAbstract:Context: Bisphosphonate-related Osteonecrosis (BON) of the Jaws is a newly identified condition for which the exact mechanism involved in its pathogenesis remains obscure. Objective: The objective of the study was to evaluate whether diabetes mellitus (DM) may be a contributing factor in the development of BON. Design: From 2004 to 2006, 31 patients were diagnosed with BON. The diagnosis of BON was based on the medical and dental history of each patient as well as the observation of clinical signs and symptoms of this pathological process. DM was based on two consecutive fasting blood glucose levels above 7 mmol/liter. Setting: The study was completed in the Hebrew University-Hadassah Hospital referral center. Results: Of the 31 patients with BON, 18 (58%) were found to have DM or impaired fasting glucose. The proportion of diabetic patients was much higher than expected relative to the incidence of DM in the general population (14%) and compared with the proportion of diabetic patients in a control group...